Cytek Biosciences Inc (CTKB)

Quick ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021
Cash	US$ in thousands	167,299	163,629	131,500	129,476	296,601	341,523	349,894	362,506	364,618	376,800	159,846
Short-term investments	US$ in thousands	95,111	124,392	167,294	169,519	44,548	—	—	—	—	—	—
Receivables	US$ in thousands	55,928	55,402	49,624	43,100	48,864	39,636	36,811	30,406	29,760	29,450	24,029
Total current liabilities	US$ in thousands	56,226	58,693	53,591	56,517	49,040	41,494	42,350	42,803	33,181	30,014	28,165
Quick ratio		5.66	5.85	6.50	6.05	7.95	9.19	9.13	9.18	11.89	13.54	6.53

December 31, 2023 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($167,299K + $95,111K + $55,928K) ÷ $56,226K
= 5.66

The quick ratio of Cytek Biosciences Inc has been consistently strong over the past several quarters, indicating a robust ability to meet its short-term obligations using its most liquid assets. The ratio has ranged from 5.66 to 13.54, with the highest being in the latest quarter. This suggests that the company has a significant amount of highly liquid assets relative to its current liabilities, providing a strong cushion for any short-term financial challenges. The increasing trend in the quick ratio over the quarters reflects a positive liquidity position for Cytek Biosciences Inc, which may enhance its financial stability and ability to weather uncertainties in the business environment.